Lu et al. observed that Rk1 could inhibit the progression of HepG2 HCC by inhibiting the ERK/c-Myc pathway, downregulating the expression of glutaminase GLS1, reducing the production of glutathione GSH, stimulating ROS accumulation, and inducing apoptosis (Lu et al., 2022). This evidence concerns the gene MYC and hepatocellular carcinoma.